Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clene Inc.CLNN · Entity 7166 | Chief Medical Officer | May 16, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clene Inc.
Report date May 16, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,564 |
Reported balance
After 2022-05-16 transaction · row 1
1 source rowRow 1 · 2022-05-16 · Sale · Disposed 4,717 · Balance 10,564 F1: The sales reported in this Form 4 represent shares of common stock of Clene Inc. required to by sold by Mr. Glanzman to satisfy tax withholding obligations in connection with the vesting of restricted stock awards. The sale occurred automatically to satisfy the tax withholding obligation to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan and does not represent a discretionary transaction by Mr. Glanzman. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 represent shares of common stock of Clene Inc. required to by sold by Mr. Glanzman to satisfy tax withholding obligations in connection with the vesting of restricted stock awards. The sale occurred automatically to satisfy the tax withholding obligation to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan and does not represent a discretionary transaction by Mr. Glanzman.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 18, 2022 08:34 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 4,717 | $2.03 | $9,575.51 |
DisclosureSEC source: 0001562180-22-004174 · primarydocument.xml · nonDerivative · entry 1 Glanzman Robert · CIK 0001835428 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,564 F1 · shares: The sales reported in this Form 4 represent shares of common stock of Clene Inc. required to by sold by Mr. Glanzman to satisfy tax withholding obligations in connection with the vesting of restricted stock awards. The sale occurred automatically to satisfy the tax withholding obligation to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan and does not represent a discretionary transaction by Mr. Glanzman. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 09:02 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 140,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001562180-22-001501 · primarydocument.xml · derivative · entry 1 Glanzman Robert · CIK 0001835428 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: This option was granted on February 15, 2022 as an option for 140,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $3.04 per share. The options vest with respect to the first 25% of such shares on February 15, 2023 and then in 36 equal installments of the balance of the shares of Common Stock on the 15th day of each calendar month thereafter beginning March 15, 2023 until such shares are fully vested. Read SEC document |
| November 04, 2021 Filed Nov 4, 2021 18:57 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 100,000 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001562180-21-006854 · primarydocument.xml · derivative · entry 1 Glanzman Robert · CIK 0001835428 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-11-04 F1 · derivative.exercise_date: This option was granted on November 4, 2021 as an option for 100,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $4.74 per share. The options vest with respect to the first 25% of such shares on November 4, 2022 and then in 36 equal installments of Common Stock on the last day of each calendar month, beginning November 30, 2022, until such shares are fully vested Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 09:20 UTC | Clene Inc. CLNN · Entity 7166 | GrantCommon Stock | 15,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004607 · primarydocument.xml · nonDerivative · entry 1 Glanzman Robert · CIK 0001835428 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,281 F1 · shares: This restricted stock award was granted on June 30, 2021 under the Clene Inc. 2020 Stock Plan. The award fully vests on January 15, 2022. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 17:16 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 95,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001562180-21-003058 · primarydocument.xml · derivative · entry 1 Glanzman Robert · CIK 0001835428 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-04-30 F1 · shares: This option was granted on April 30, 2021 under the Clene Inc. 2020 Stock Plan. The options vest with respect to the first 25% on May 31, 2022 and then in 36 equal installments of 1/48th of the balance on the last day of each calendar month, beginning June 30, 2022, until fully vested F1 · derivative.exercise_date: This option was granted on April 30, 2021 under the Clene Inc. 2020 Stock Plan. The options vest with respect to the first 25% on May 31, 2022 and then in 36 equal installments of 1/48th of the balance on the last day of each calendar month, beginning June 30, 2022, until fully vested Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.